Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors

Jiang, Zaixin; Li, Yang; Cao, Yan; Zhang, Xiaolin; Zhang, Quanyu; Li, Jing; Tian, Xiaoxiang; Qiu, Miaohan; Liang, Zhenyang; Ma, Sichong; Na, Kun; Li, Ziqi; Chen, Sanbao; Zhao, Yu; Qi, Zizhao; Liu, Xiying; Han, Yaling

doi:10.1007/s00392-022-02039-6

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Association of CHIP with the combined endpoint was independent of age and biomarkers reflecting kidney function, heart failure severity, and inflammation. 43 Recently, Jiang et al 44 in a series of 179 patients with acute coronary syndrome who underwent percutaneous coronary intervention in absence of traditional cardiovascular risk factors detected CHIP-related mutations in 20% of cases. In this cohort, the somatic mutations most frequently occurred in the genes DNMT3A, TET2, and ASXL1, and were associated with significantly higher risk of recurrent major adverse cardiac or cerebral events.…”

Section: Clonal Hematopoiesis Of Undetermined Significance In Atheros...mentioning

confidence: 99%

“…In this cohort, the somatic mutations most frequently occurred in the genes DNMT3A, TET2, and ASXL1, and were associated with significantly higher risk of recurrent major adverse cardiac or cerebral events. 44 In a recent cohort study of 13 129 patients aged 40-70 years and with established atherosclerotic CVD, both CHIP and CHIP with VAF at least 10% were independently associated with adjusted hazard ratios of 1.23 [95% confidence interval (95% CI): 1.10-1.38; P < 0.001] and 1.34 (95% CI: 1.17-1.53; P < 0.001), respectively, for the primary outcome (composite of atherosclerotic CVD event and all-cause mortality) over a median follow-up of 10.8 years. In particular, especially high risks were observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP (spliceosome genes).…”

Section: Clonal Hematopoiesis Of Undetermined Significance In Atheros...mentioning

confidence: 99%

See 1 more Smart Citation

Clonal hematopoiesis of indeterminate potential: implications for the cardiologists

Sciatti,

D’Elia,

Gori

et al. 2023

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are characterized by somatic gene mutations in bone marrow stem cells, which trigger an inflammatory response influencing the development of associated cardiovascular complications. In recent years, the same mutations were found in individuals with cardiovascular diseases even in the absence of hematological alterations. These genetic events allow the identification of a new entity called ‘clonal hematopoiesis of indeterminate potential’ (CHIP), as it was uncertain whether it could evolve toward hematological malignancies. CHIP is age-related and, remarkably, myocardial infarction, stroke, and heart failure were frequently reported in these individuals and attributed to systemic chronic inflammation driven by the genetic mutation. We reviewed the connection between clonal hematopoiesis, inflammation, and cardiovascular diseases, with a practical approach to improve clinical practice and highlight the current unmet needs in this area of knowledge.

show abstract

Section: Clonal Hematopoiesis Of Undetermined Significance In Atheros...mentioning

confidence: 99%

Section: Clonal Hematopoiesis Of Undetermined Significance In Atheros...mentioning

confidence: 99%

Clonal hematopoiesis of indeterminate potential: implications for the cardiologists

Sciatti,

D’Elia,

Gori

et al. 2023

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations

Liu,

Cheng,

Cheng

et al. 2024

Hematology

View full text Add to dashboard Cite

Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis

Singh,

Li,

Ashrafi

et al. 2024

Blood Advances

View full text Add to dashboard Cite

With advances in sequencing, individuals with clonal hematopoiesis of indeterminate potential (CHIP) are increasingly being identified, making it essential to understand its prognostic implications. We conducted a systematic review of studies comparing the risk of clinical outcomes in individuals with and without CHIP. We searched MEDLINE and EMBASE, and included original research reporting an outcome risk measure in individuals with CHIP, adjusted for the effect of age. From 3305 studies screened, we included 88 studies of 45 to 470960 participants. Most studies had low to moderate risk of bias in all domains of the QUIPS tool. Random effects meta-analyses were performed for outcomes reported in at least 3 studies. CHIP conferred increased risk of all-cause mortality (hazard ratio [HR] 1.34 [95% CI 1.19-1.50]), cancer-mortality (HR 1.46 [1.13-1.88]), composite cardiovascular events (HR 1.40 [1.19-1.65]), coronary heart disease (HR = 1.76 [1.27-2.44]), stroke (HR 1.16 [1.05-1.28]), heart failure (HR 1.27 [1.15-1.41]), hematologic malignancy (HR 4.28 [2.29-7.98]), lung cancer (HR 1.40 [1.27-1.54]), renal impairment (HR 1.25 [1.18-1.33]) and severe COVID19 (odds ratio [OR] 1.46 [1.18-1.80]). CHIP was not associated with cardiovascular mortality (HR 1.09 [0.97-1.22]), except in subgroup analysis restricted to larger clones (HR 1.31 [1.12-1.54]). Isolated DNMT3A mutations did not increase risk of myeloid malignancy, all-cause mortality or renal impairment. Reasons for heterogeneity between studies included differences in definitions and measurement of CHIP and outcomes, and populations studied. In summary, CHIP is associated with diverse clinical outcomes, with clone size, specific gene and inherent patient characteristics important mediators of risk.

show abstract

Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors

Cited by 3 publications

References 27 publications

Clonal hematopoiesis of indeterminate potential: implications for the cardiologists

Clonal hematopoiesis of indeterminate potential: implications for the cardiologists

Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations

Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis

Contact Info

Product

Resources

About